# Legend Biotechnology

Carvykti (ciltacabtagene autoleucel) is a BCMA CAR-T for relapsed/refractory multiple myeloma, advanced through the LEGEND-2 programme and a growing real-world evidence base.

Source: https://en.bioecon.ru/companies/legend-biotechnology/
Updated: 2026-07-11

- Country: China
- Ticker: LEGN

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $1.9 billion in FY 2025 net trade sales for CARVYKTI; $597 million in Q1 2026 net trade sales for CARVYKTI | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://investors.legendbiotech.com/static-files/9d4e28b5-d67a-4af5-88c4-8649a1d17cfc, https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results, https://www.sec.gov/Archives/edgar/data/1801198/000117184325003764/exh_991.htm, https://www.sec.gov/Archives/edgar/data/1801198/000117184326000206/exh_991.htm |
| Headcount | Approximately 6,316 employees as of March 2026 | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results |
| Production site | Raritan, NJ (US); Obelisc and Tech Lane in Ghent, Belgium (EU); Morris Plains, NJ (CMO) | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://www.sec.gov/Archives/edgar/data/1801198/000117184325003764/exh_991.htm, https://www.sec.gov/Archives/edgar/data/1801198/000117184326000206/exh_991.htm |
| Capacity | Installed capacity to support treatment of up to 10,000 patients annually at the expanded Raritan facility as of 2026 | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results, https://www.sec.gov/Archives/edgar/data/1801198/000117184325003764/exh_991.htm, https://www.sec.gov/Archives/edgar/data/1801198/000117184326000206/exh_991.htm |
| Regulatory approval | CARVYKTI is approved for relapsed/refractory multiple myeloma in the US, Europe, Japan, Brazil, Canada, and China (4L+) | https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-announces-acceptance-its-new-drug-application, https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://legendbiotech.gcs-web.com/node/8856/pdf, https://www.myeloma.org/treatment/carvykti-ciltacabtagene-autoleucel |
| Funding | $350 million upfront payment from Janssen for worldwide license (2017); $423.8 million in gross proceeds from Nasdaq listing (2020) | https://www.sec.gov/Archives/edgar/data/1801198/000115752322000455/a52692636ex99_1.htm, https://www.thepharmaletter.com/ones-to-watch/legend-biotech |

Independent sources: investors.legendbiotech.com, myeloma.org, sec.gov, thepharmaletter.com

## Technologies

- [CAR-T cell therapy](https://en.bioecon.ru/technology/car-t-cell-therapy/)